ARIAD is developing a new class of pharmaceuticals that target intracellular signaling pathways to alter the course of disease.
LaMarche, Chief Financial Officer of ARIAD Pharmaceuticals, 617-494-0400/
Pharmaceuticals is engaged in the discovery and development of pharmaceuticals that target intracellular communications pathways to alter the course of disease.
March 27 /PRNewswire/ -- ARIAD Pharmaceuticals, Inc.
Blech & Company, Incorporated served as placement agents for the ARIAD offering.
In order to create additional value for our stockholders, the independent and disinterested members of the ARIAD Board undertook, with the assistance of an investment banking firm, an extensive evaluation of strategic alternatives with respect to acquiring the 20 percent minority interest of AGTI that ARIAD did not own," stated Sandford D.
Upon the consummation of this merger, ARIAD is poised to realize all of the potential future economic benefit from deforolimus and other assets previously owned by AGTI," stated Dr.
Deputy Director of SARC, Co-Director of the Adult Sarcoma Program at Memorial Sloan-Kettering Cancer Center, Assistant Professor of Medicine at Weill Medical College of Cornell University - and one of the lead investigators of the Phase 3 trial - discussed how SARC and EORTC will work together with ARIAD to leverage their world-renowned network of sarcoma experts and clinicians for participation in the collaborative Phase 3 trial.
The discussion and slides used at the investor event will be available on the ARIAD website (http://www.
Earlier this year, at the American Society of Clinical Oncology annual meeting, ARIAD announced that AP23573 demonstrated efficacy and was well tolerated as a single agent in this multi-center Phase 2 trial of patients with advanced sarcomas, at least 90% of whom had progressive disease.
In addition to its program in oncology, ARIAD is collaborating with Medinol Ltd to develop stents and other medical devices that deliver AP23573 to prevent reblockage at sites of vascular injury following stent-assisted angioplasty.
senior vice president and chief scientific officer of ARIAD
, added, "Our mTOR inhibitor programs, including AP23573, evolved directly from scientific discoveries made in our ARGENT technology program.